NASH Core Curriculum: A Comprehensive Online Resource Center

Learn about the impact of NASH and the interplay with diabetes, obesity, and cardiovascular disease.

Brent A. Neuschwander-Tetri, MD Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: February 3, 2021 Expired: No longer available for credit

What Is NASH?

What Is the Relationship Between NASH and Other Metabolic Disturbances?

Is NASH Reversible?

Learn about the impact of NASH and the interplay with diabetes, obesity, and cardiovascular disease.

Brent A. Neuschwander-Tetri, MD Released: February 3, 2021

The pathogenesis of NASH is complex, but there’s insight in looking at diabetes, obesity, and insulin resistance through the lens of the liver.

Brent A. Neuschwander-Tetri, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: January 29, 2021 Expired: No longer available for credit

Learn about who is at risk and who should be evaluated for progression to advanced fibrosis in NASH.

Manal F. Abdelmalek, MD, MPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: March 15, 2021 Expired: No longer available for credit

How Prevalent Are NASH and NASH with Advanced Hepatic Fibrosis?

How Quickly Does NASH Progress?

Who Is at Risk for Progression to Advanced Hepatic Fibrosis?

Learn about who is at risk and should be evaluated for progression to advanced fibrosis in NASH.

Manal F. Abdelmalek, MD, MPH Released: March 15, 2021

AASLD guidelines do not recommend routine screening for NAFLD or NASH, but they and other guidelines do call out patients with type 2 diabetes as warranting workup.

Manal F. Abdelmalek, MD, MPH Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: March 16, 2021 Expired: No longer available for credit

Learn how to use noninvasive tests to identify individuals with NAFLD and determine their risk of progression to NASH fibrosis.

Wing-Kin Syn, MBChB, PhD, FACP, FRCP Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: April 27, 2021 Expired: No longer available for credit

Introduction

Identifying Individuals With NAFLD

Risk Stratifying NAFLD: Tools to Identify Significant or Advanced Hepatic Fibrosis

Clinical or Laboratory Scores

Proprietary Biomarkers

Imaging

Sequential Tests

Learn the best tools and approaches to identify NAFLD and to rule in or rule out NASH fibrosis.

Wing-Kin Syn, MBChB, PhD, FACP, FRCP Released: April 27, 2021

With the many noninvasive tests available for screening those who are at risk for NAFLD/NASH, where should we begin and what is the optimal sequence of testing? Here’s my approach.

Wing-Kin Syn, MBChB, PhD, FACP, FRCP Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: April 20, 2021 Expired: No longer available for credit

Hear expert insights on the roles of currently available approaches—and the most recent evidence—for managing NASH.

Giada Sebastiani, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: June 2, 2021 Expired: No longer available for credit

Lifestyle

Recommended Pharmacologic Therapies for NASH

Role of Current Diabetes Therapies in NAFLD/NASH

Learn the roles of currently available approaches—and the most recent evidence—for managing NASH.

Giada Sebastiani, MD Released: June 2, 2021

There are no FDA-approved treatments for NASH. But there are still ways to manage it.

Giada Sebastiani, MD Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: June 2, 2021 Expired: No longer available for credit

Hear expert insights on emerging approaches for managing NASH, targeting both hepatic and extrahepatic manifestations.

Stephen Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: July 20, 2021 Expired: July 19, 2022

Where Did We Start?

Where Are We Going?

Hepatic Outcomes

Extrahepatic Outcomes

Hear expert perspectives on histologic and metabolic endpoints in NASH studies and how they may inform potential targets for oral, injectable, and combination NASH treatments.

Stephen Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC Released: July 20, 2021

My take on how emerging drugs are measuring up.

Stephen Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC Physicians: maximum of 0.25 AMA PRA Category 1 Credits™ Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: September 17, 2021 Expired: September 16, 2022

Expert recap of highlights from the NASH Core Curriculum, including pathogenesis, risk factors, and current and emerging therapies for patients with NAFLD/NASH.

Stephen Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC Physicians: maximum of 0.5 AMA PRA Category 1 Credits™ Registered Nurses: 0.5 Nursing contact hours Pharmacists: 0.5 contact hours (0.05 CEUs) Released: September 9, 2021 Expired: September 8, 2022

Prevalence and Pathogenesis

Risk Factors and Screening

Current Management

Emerging Agents

Expert recap of highlights from the NASH Core Curriculum, including pathogenesis, risk factors, and current and emerging therapies for patients with NAFLD/NASH.

Stephen Harrison, MD, FACP, FAASLD, COL (ret.) USA, MC Released: September 9, 2021

Easy-to-read reminders on why and how to look for NAFLD and NASH in your patients.

Download for your patients and their caregivers: patient-friendly overview of the impact of NASH, including its high prevalence and consequences, plus currently recommended approaches to NASH management.